Patents by Inventor David Strayer

David Strayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9969491
    Abstract: A drone launch system includes a canister defining an internal cavity, and a drone positioned within the internal cavity in a stowed state. The drone is configured to be ejected from the canister and transition from the stowed state into a deployed state outside of the canister. A method for launching a drone, the method includes positioning the drone in a stowed state in an internal cavity of a canister, ejecting the drone from the canister, and transitioning the drone into a deployed state after the ejecting operation.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: May 15, 2018
    Assignee: The Boeing Company
    Inventor: James David Strayer
  • Publication number: 20170057635
    Abstract: A drone launch system includes a canister defining an internal cavity, and a drone positioned within the internal cavity in a stowed state. The drone is configured to be ejected from the canister and transition from the stowed state into a deployed state outside of the canister. A method for launching a drone, the method includes positioning the drone in a stowed state in an internal cavity of a canister, ejecting the drone from the canister, and transitioning the drone into a deployed state after the ejecting operation.
    Type: Application
    Filed: September 2, 2015
    Publication date: March 2, 2017
    Applicant: The Boeing Company
    Inventor: James David Strayer
  • Patent number: 9315538
    Abstract: The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: April 19, 2016
    Assignee: HEMISPHERX BIOPHARMA, INC.
    Inventors: William A. Carter, David Strayer
  • Publication number: 20150064216
    Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
    Type: Application
    Filed: November 11, 2014
    Publication date: March 5, 2015
    Inventors: William A. CARTER, David STRAYER
  • Publication number: 20140235841
    Abstract: The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 21, 2014
    Applicant: HEMISPHERx BIOPHARMA, INC.
    Inventors: William A. CARTER, David STRAYER
  • Publication number: 20120004290
    Abstract: Chronic fatigue syndrome and prolonged QT interval are treated using one or more different double-stranded ribonucleic acids (dsRNA).
    Type: Application
    Filed: March 10, 2010
    Publication date: January 5, 2012
    Inventors: David Strayer, William A. Carter
  • Patent number: 8075878
    Abstract: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human ?-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: December 13, 2011
    Assignee: Hemispherx Biopharma
    Inventors: William A. Carter, David Strayer
  • Publication number: 20110223198
    Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
    Type: Application
    Filed: April 19, 2011
    Publication date: September 15, 2011
    Applicant: HEMISPHERx BIOPHARMA
    Inventors: William A. Carter, David Strayer
  • Publication number: 20110196020
    Abstract: A subset of human patients having chronic fatigue syndrome and impaired physical performance is treated using one or more different double-stranded ribonucleic acids (dsRNA) or other selective agonists of Toll-like receptor 3 (TLR3).
    Type: Application
    Filed: October 13, 2009
    Publication date: August 11, 2011
    Inventors: William A. Carter, David Strayer
  • Patent number: 7943147
    Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: May 17, 2011
    Assignee: Hemispherx Biopharma
    Inventors: William A. Carter, David Strayer
  • Publication number: 20110044946
    Abstract: A mixture of ?-interferons (IFN-?) is used in vitro or in vivo as an antimicrobial agent or anticancer agent. It may be administered by topical application to oral or nasal, and/or buccal mucosa to combat the effects of infection by bacteria or protozoa, cancer, or other pathogenic disease process (e.g., autoimmune or neurodegenerative disease).
    Type: Application
    Filed: February 17, 2009
    Publication date: February 24, 2011
    Inventors: William A. Carter, David Strayer
  • Publication number: 20100310600
    Abstract: A mismatched double-stranded ribonucleic acid, which is an agonist for Toll-like receptor 3 (TLR3), is used in vitro or in vivo as an antimicrobial agent, antiproliferative agent, and/or immunostimulant. Poly(l:C11-14U) is a more selective agonist of TLR3 as compared to poly(l:C) even though the both double-stranded RNA are structurally analogous.
    Type: Application
    Filed: February 17, 2009
    Publication date: December 9, 2010
    Inventors: William A. Carter, David Strayer
  • Publication number: 20100160413
    Abstract: The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.
    Type: Application
    Filed: November 13, 2009
    Publication date: June 24, 2010
    Applicant: HEMISPHERx BIOPHARMA, INC.
    Inventors: William A. Carter, David Strayer
  • Publication number: 20100104533
    Abstract: Symptoms of viral infection are mitigated by administering to a subject exposed to a virus a protective or symptom-mitigating amount of a dsRNA and continuing administration until the subject's symptoms have improved.
    Type: Application
    Filed: June 18, 2008
    Publication date: April 29, 2010
    Inventors: William A. Carter, David Strayer
  • Patent number: 7693697
    Abstract: A method, system and apparatus for the monitoring, diagnosis and evaluation of the state of a dynamic drug display system is disclosed. This invention provides for the rapid cognitive grasp of the overall state of drug combination effects with respect to a dynamic system. The system provides for displayed objects, which change in real-time to show the changes of the functions of the system. In particular, this invention is directed to the processing and display of drug data for the use of doctors in the process of monitoring or administering drugs to patients.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: April 6, 2010
    Assignee: University of Utah Research Foundation
    Inventors: Dwayne Westenskow, James Agutter, Noah Syroid, David Strayer, Robert Albert, Frank Drews
  • Patent number: 7678774
    Abstract: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: March 16, 2010
    Assignee: Hemispherx Biopharma
    Inventors: William A. Carter, David Strayer
  • Patent number: 7654966
    Abstract: A method, system, apparatus and device for the monitoring, diagnosis and evaluation of the state of a dynamic pulmonary system is disclosed. This method and system provides the processing means for receiving sensed and/or simulated data, converting such data into a displayable object format and displaying such objects in a manner such that the interrelationships between the respective variables can be correlated and identified by a user. This invention provides for the rapid cognitive grasp of the overall state of a pulmonary critical function with respect to a dynamic system.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: February 2, 2010
    Assignee: University of Utah Research Foundation
    Inventors: Dwayne Westinskow, James Agutter, Noah Syroid, David Strayer, Robert Albert, S. Blake Wachter, Frank Drews
  • Publication number: 20090304630
    Abstract: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase influenza virus inhibitor. These two products, dsRNA, and alpha interferon, have therapeutic utility either given preventively (prophylactically) or in treatment of active disease. These unique immunological/antiviral actions, operating through immunological “cascades” ameliorates the lethal effects of viral mutation which, by causing resistance to commonly available drugs, greatly accelerates the death rate. For example, in 1918-1920, Avian Influenza caused the death of approximately 40 million people worldwide (ref. National Geographic, September, 2005).
    Type: Application
    Filed: August 2, 2007
    Publication date: December 10, 2009
    Applicant: HEMISPHERx BIOPHARMA
    Inventors: William A. Carter, David Strayer
  • Patent number: D660749
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: May 29, 2012
    Inventor: David Strayer
  • Patent number: D661623
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: June 12, 2012
    Inventor: David Strayer